Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewTopiramate is an anticonvulsant. Antagonizes GluK1 (formerly GluR5) kainate receptors (IC50 = 0.46 μM), acts as a positive allosteric modulator of GABAA receptor-mediated currents, inhibits Nav channels (IC50 = 48.9 μM) and inhibits L-type Ca2+ channels. Also inhibits carbonic anhydrase (CA) (Ki values are 0.1 and 0.2 μM at rat CA II and CA IV respectively), which lowers intracellular neuronal pH.
Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.
Topiramate is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen FDA-Approved Drugs. Find out more about compound libraries available from Tocris.
M. Wt | 339.36 |
Formula | C12H21NO8S |
Storage | Store at +4°C |
Purity | ≥99% (HPLC) |
CAS Number | 97240-79-4 |
PubChem ID | 5284627 |
InChI Key | KJADKKWYZYXHBB-XBWDGYHZSA-N |
Smiles | CC(O2)(C)O[C@H]1[C@@H]2[C@H](OC(C)(C)O3)[C@@]3(COS(N)(=O)=O)OC1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 33.94 | 100 | |
ethanol | 33.94 | 100 |
The following data is based on the product molecular weight 339.36. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 2.95 mL | 14.73 mL | 29.47 mL |
5 mM | 0.59 mL | 2.95 mL | 5.89 mL |
10 mM | 0.29 mL | 1.47 mL | 2.95 mL |
50 mM | 0.06 mL | 0.29 mL | 0.59 mL |
References are publications that support the biological activity of the product.
Zona et al (1997) Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci.Lett. 231 123 PMID: 9300637
Dodgson et al (2000) Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 41 S35 PMID: 10768298
Gryder and Rogawski (2003) Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topir. in rat basolateral amygdala neurons. J.Neurosci. 23 7069 PMID: 12904467
Kaminiski et al (2004) Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 46 1097 PMID: 15111016
If you know of a relevant reference for Topiramate, please let us know.
Keywords: Topiramate, Topiramate supplier, GluR5, antagonists, anticonvulsant, GABAA, receptor, positive, allosteric, modulators, Glutamate, Kainate, Receptors, iGluR, Ionotropic, GluK1, PAM, Topamax, Carbonic, anhydrases, 3620, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for Topiramate. Do you know of a great paper that uses Topiramate from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review Topiramate and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.